International Journal of Clinical Oncology

, Volume 14, Issue 2, pp 85–89 | Cite as

Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis

Review Article

Abstract

A consensus regarding standard adjuvant chemotherapy for curatively resected gastric cancer has not been obtained between Japan and the Western world. In order to evaluate the effect of a tegafur-based regimen (the most frequently used regimen in Japan) compared with a surgery-alone control, a meta-analysis was performed, investigating four clinical trials. After meticulous examination of each trial, trials with improper noncentralized randomization were excluded from the analysis. A total of 1197 patients were enrolled in the four relevant trials determined to be eligible for the meta-analysis (Nakajima 1984; Japan Clinical Oncology Group [JCOG] 8801, JCOG 9206-2, and National Surgical Adjuvant Study of Gastric Cancer [NSASGC], in which a tegafur-based regimen was used for chemotherapy and central randomization was performed. The endpoint was overall survival, and a common hazard ratio was estimated. The 5-year overall survival rates differed among the trials because of differences in the background disease status. But there was no heterogeneity (P = 0.235) of treatment effect. The estimated common hazard ratio was 0.75, with a 95% confidence interval of 0.58–0.98. The treatment effect of the tegafur-based agent was shown to be statistically significant (P = 0.037) compared with surgery-alone therapy (n = 1179). From the results of the above meta-analysis, it is suggested that chemotherapy with a tegafur-based agent after surgery can improve the survival of patients with curatively resected gastric cancer. The Global Advanced/Adjuvant Stomach Tumor Research through International Collaboration (GASTRIC) group is conducting two individual patient data meta-analyses, testing post-operative adjuvant chemotherapy for resect-able gastric cancer and chemotherapy for advanced gastric cancer. It is expected to determine and quantify the role of adjuvant chemotherapy in detail from the GASTRIC.

Key words

Adjuvant chemotherapy Gastric cancer Meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002 (2004) Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. IARC, LyonGoogle Scholar
  2. 2.
    Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:204–213PubMedGoogle Scholar
  3. 3.
    Macdonald JS, Smalley SR, Benedetti J, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRefGoogle Scholar
  4. 4.
    Macdonald JS (2004) Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 54:S4–S11PubMedGoogle Scholar
  5. 5.
    Maehara Y, Baba H, Sugimachi K (2001) Adjuvant chemotherapy for gastric cancer: a comprehensive review. Gastric Cancer 4:175–184PubMedCrossRefGoogle Scholar
  6. 6.
    Saka M, Sasako M, Katai H, et al. (2000) Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer (in Japanese). Jpn J Cancer Chemother 27:2033–2042Google Scholar
  7. 7.
    Sasaki T (2004) In regard to gastric cancer treatment guidelines — a revised edition (in Japanese). Jpn J Cancer Chemother 21:1947–1951Google Scholar
  8. 8.
    Oba K, Morita S, Tsuburaya A, et al. (2006) Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 18:311–317PubMedGoogle Scholar
  9. 9.
    Sakamoto J, Morita S, Kodera Y, et al. (2004) Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 54:S25–S31PubMedCrossRefGoogle Scholar
  10. 10.
    Ohta K (2000) Present status of treatment for stomach cancer in Japan (from the questionnaire) (in Japanese). J Ther 82:1782–1783Google Scholar
  11. 11.
    Parmar MB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRefGoogle Scholar
  12. 12.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  13. 13.
    Nakajima T, Takahashi T, Takagi K, et al. (1984) Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 2:1366–1371PubMedGoogle Scholar
  14. 14.
    Honda I, Watanabe S, Fujita Y (1997) Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer (in Japanese). Jpn J Cancer Chemother 24:1109–1117Google Scholar
  15. 15.
    Tsugita M, Takasaki K, Yagawa A, et al. (1992) An evaluation of perioperative and continuous infusion of tegafur as surgical adjuvant chemotherapy of resected gastric cancer (in Japanese). Jpn J Cancer Chemother 19:333–337Google Scholar
  16. 16.
    Nakajima T, Nashimoto A, Kitamura M, et al. (1999) Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Gastric Cancer Surgical Study Group. Lancet 354:273–277PubMedCrossRefGoogle Scholar
  17. 17.
    Yoshino H, Fujita M, Hirata K, et al. (2000) Interim report on JFMTC Study no.21 on effectiveness of UFT as an adjuvant therapy for semi-advanced cancer of the stomach (in Japanese). Jpn J Cancer Chemother 27:263–270Google Scholar
  18. 18.
    Miyashiro I, Furukawa H, Sasako M, et al. (2005) No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer: Japan Clinical Oncology Group 9206-2. 2005 Gastrointestinal Cancers Symposium Proceedings Miami, Jan 27–29: abstract no.4Google Scholar
  19. 19.
    Kinoshita T, Nakajima T, Ohashi Y, et al. (2005) Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: results of a randomized trial by National Surgical Adjuvant Study Of Gastric Cancer. Proc Am Soc Clin Oncol 23:313sGoogle Scholar
  20. 20.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRefGoogle Scholar
  21. 21.
    Di Costanzo F, Gasperoni S, Manzione L, et al. (2008) Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100:388–398PubMedCrossRefGoogle Scholar
  22. 22.
    Kattan MW, Karpeh MS, Mazumdar M, et al. (2003) Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21:3647–3650PubMedCrossRefGoogle Scholar
  23. 23.
    Kikuchi S, Sakakibara Y, Sakuramoto S, et al. (2001) Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. Anticancer Res 21:3589–3593PubMedGoogle Scholar
  24. 24.
    Sakamoto J, Paoletti X, on behalf of the Global Adv/Adj Stomach Tumor Research through International Collaboration (GASTRIC). (2008) Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy in gastric cancer. Proc Am Soc Clin Oncol 26:4543sGoogle Scholar
  25. 25.
    Rougier P, Oba K, on behalf of the Global Adv/Adj Stomach Tumor Research through International Collaboration (GASTRIC). (2008) Meta-analyses of randomized trials assessing the interest chemotherapy in advanced gastric cancer. Proc Am Soc Clin Oncol 26:4563sGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2009

Authors and Affiliations

  1. 1.EBM Research CenterKyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations